ArticleFrontiers in pharmacology2025

Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Ming Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.